Loading stock data…
INVA
$22.54+0.21 (+0.94%)
After Hours$22.54+0.00 (+0.00%)· Last close Jun 9
Innoviva, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Innoviva, Inc. in the Healthcare sector is trading at $22.54. Wall Street consensus targets $35.50 (4 analysts), implying a +57.5% move over the next 12 months. The stock is currently 10% below its 52-week high of $25.15, remaining 7.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +57.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$22.54
Potential Downside
0%
Whystock Fair Value$22.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$35.50+57.5%
Range$18.00 – $46.00
Fundamentals
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
37.59%
Volume
Today's trading volume
722,356
Recent News
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?
Wondering whether Innoviva's current share price reflects its true worth, or if the stock might be mispriced. After some shorter term share price weakness, with the stock down 0.4% over the past week and 3.7% over the past month, Innoviva is still up 15.2% year to date and 23.0% over the last year. Those moves sit against a backdrop of ongoing attention on Innoviva's position in the pharmaceuticals space and on how investors weigh its portfolio and balance sheet against sector peers. Recent...
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength
Innoviva, Inc. (NASDAQ:INVA) is one of the best small-cap value stocks to buy. On April 8, Cantor Fitzgerald reiterated an Overweight rating on Innoviva Inc. (NASDAQ:INVA) and a $32 price target. The research firm remains confident about the company’s prospects, owing to the stability of its recurring royalty business that generated about $250 million in […]
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
3 Bargain-Cheap Small Caps Worth a Second Look
Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally